NYSE:ANVS Annovis Bio Q4 2024 Earnings Report $2.13 -0.09 (-3.83%) Closing price 05/14/2026 03:58 PM EasternExtended Trading$2.12 -0.02 (-0.94%) As of 07:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Annovis Bio EPS ResultsActual EPS-$0.43Consensus EPS -$0.38Beat/MissMissed by -$0.05One Year Ago EPS-$0.43Annovis Bio Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAnnovis Bio Announcement DetailsQuarterQ4 2024Date3/21/2025TimeAfter Market ClosesConference Call DateFriday, March 21, 2025Conference Call Time12:00AM ETUpcoming EarningsAnnovis Bio's Q1 2026 earnings is estimated for Tuesday, May 19, 2026, based on past reporting schedules, with a conference call scheduled on Monday, May 18, 2026 at 12:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Annovis Bio Earnings HeadlinesAnnovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026May 7, 2026 | globenewswire.comAnnovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature PortfolioApril 28, 2026 | globenewswire.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.May 15 at 1:00 AM | InvestorPlace (Ad)Annovis Bio Inc.April 20, 2026 | barrons.comAnnovis Bio (ANVS) price target increased by 13.94% to 15.98April 10, 2026 | msn.comAnnovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA SubmissionApril 10, 2026 | globenewswire.comSee More Annovis Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Annovis Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Annovis Bio and other key companies, straight to your email. Email Address About Annovis BioAnnovis Bio (NYSE:ANVS) (NYSE: ANVS) is a clinical-stage biotechnology company headquartered in Tampa, Florida, focused on the discovery and development of small molecule therapeutics for neurodegenerative and neuroinflammatory disorders. Leveraging a proprietary platform that targets protein trafficking and translational dysregulation, Annovis aims to restore cellular homeostasis by modulating the production and clearance of disease-related proteins. The company’s pipeline is designed to address critical pathways implicated in Alzheimer’s disease, Parkinson’s disease, multiple sclerosis and other central nervous system conditions. The company’s lead asset, ANVS401 (Posiphen®), is an oral small molecule that has been evaluated in Phase 1 and Phase 2 clinical trials to reduce levels of amyloid precursor protein and its toxic fragments in Alzheimer’s patients. Preclinical studies suggest that this mechanism may also have applications in mitigating neuroinflammation. In addition to ANVS401, Annovis is advancing a second-generation program, ANVS520, which is aimed at lowering pathological tau and alpha-synuclein aggregates, key drivers of neurodegeneration in Alzheimer’s and Parkinson’s diseases. Both candidates reflect the company’s strategy of targeting multiple disease pathways with a single therapeutic approach. Annovis Bio conducts its clinical trials in North America and Europe, collaborating with academic research centers and contract research organizations to explore safety, pharmacodynamics and biomarker endpoints. The company’s leadership team brings together expertise in neurology, medicinal chemistry and drug development, with a commitment to translating early-stage research into viable treatments. As a publicly traded entity, Annovis continues to engage with scientific and investor communities to advance its programs toward potential regulatory approval.View Annovis Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles YETI Rallies After Earnings Beat and Raised OutlookCisco’s Vertical Rally May Still Be in the Early InningsHow the 3 Leading Quantum Firms Stack Up After Q1 EarningsNebius Upside Expands as AI Feedback Loop IntensifiesOklo Stock Could Be Ready for Another Massive RunAmazon vs. Alibaba: One Is Clearly The Better Value Play right NowD-Wave Earnings Looked Weak, But Investors May Be Missing This Upcoming Earnings Baidu (5/18/2026)Palo Alto Networks (5/19/2026)Home Depot (5/19/2026)Keysight Technologies (5/19/2026)Analog Devices (5/20/2026)Intuit (5/20/2026)NVIDIA (5/20/2026)Lowe's Companies (5/20/2026)Medtronic (5/20/2026)Target (5/20/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
